Project Grant R01CA297795
Award Date 9/1/26
Completion Date 8/31/29
Dollars Obligated $2.5M
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $429,162 Project Grant (CFDA 93.395, Cancer Treatment Research program) effective August 1, 2025 through July 31, 2027 to conduct a prospective feasibility study exploring the neuroprotective potential of cannabidiol (CBD) in preventing oxaliplatin-induced peripheral neuropathy in colorectal cancer patients. The research deliverables include: (1) evaluation of the feasibility and...
- The National Institute of Neurological Disorders and Stroke awarded the University of Rochester $2,197,287 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a Phase III confirmatory clinical trial of daily, wireless, home-based transcutaneous electrical nerve stimulation (TENS) for chemotherapy-induced peripheral neuropathy (CIPN). The trial will evaluate TENS efficacy in relieving neuropathic pain in cancer patients who have developed CIPN—a common...
- The National Cancer Institute awarded The Medical College of Wisconsin, Inc., a project grant of $647,147 on August 7, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate keratinocyte signaling mechanisms in chemotherapy-induced peripheral neuropathy. The research addresses how keratinocytes—the primary cell type of the epidermis—drive neuropathic pain in patients receiving chemotherapy. Painful peripheral neuropathy occurs in up to 80 percent of chemotherapy...
- The National Cancer Institute awarded Thomas Jefferson University $312,363 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to assess the feasibility of a remotely-delivered Tai Chi intervention for older gastrointestinal cancer patients experiencing chemotherapy-induced peripheral neuropathy (CIPN). The study addresses CIPN—characterized by numbness, tingling, and pain that impairs physical function and elevates fall risk—in patients aged 65 and above. The research...
- The National Cancer Institute awarded The Medical College of Wisconsin, Inc., $149,190 on January 21, 2026, under the Cancer Research Manpower program (CFDA 93.398) to fund basic research investigating the role of keratinocytes and the TRPM3 ion channel in chemotherapy-induced peripheral neuropathy (CIPN) pain. The research uses a mouse model of CIPN to examine how non-neuronal skin cells contribute to ongoing pain behaviors following paclitaxel chemotherapy exposure. In Aim 1, the...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke awarded The Johns Hopkins University a $2.71 million Project Grant (effective August 6, 2025 through July 31, 2030) under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the neurobiological mechanisms underlying paclitaxel-induced peripheral neuropathy (PIPN). The award supports research utilizing novel whole dorsal root ganglia (DRG) in vivo imaging technology to monitor sensory...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded Oregon Health & Science University $544,420 on August 15, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to conduct a clinical trial testing the efficacy of low-intensity vibration therapy in reducing chemotherapy-induced peripheral neuropathy symptoms and preserving functional mobility in cancer survivors. The research will evaluate whether low-intensity...
- This $419,474 project grant from the National Cancer Institute, part of the Department of Health and Human Services, supports research under the Cancer Treatment Research program to develop mechanism-based strategies to treat chemotherapy-induced peripheral neuropathy. The awardee, Washington University, will utilize a SARM1 dominant-negative construct and virus-mediated overexpression of NAD+ salvage pathway enzymes to block the axon degeneration pathway activated by chemotherapeutic agents...
- The National Institute of Neurological Disorders and Stroke awarded the University of Massachusetts Lowell $2.272 million on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to discover novel, non-opioid, non-addictive analgesics derived from marine microbial natural products. The award funds a phenotypic screening effort combining human induced pluripotent stem cell sensory neurons and glia cultured on multi-well microelectrode arrays to characterize sensory neuron...
- The National Institute of Neurological Disorders and Stroke awarded Weill Medical College of Cornell University $635,074 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop HCN1-selective nanobodies for use in novel, non-opioid antihyperalgesia therapeutics targeting neuropathic pain. The project focuses on creating an HCN1-selective nanobody and identifying critical geometric features of the human HCN1 ion channel to guide antibody-drug conjugate...